Top Story

Average cost per SVR12 was $171,000 for Olysio, Sovaldi regimens

March 2, 2015

SEATTLE — The mean cost per sustained virologic response at 12 weeks among a cohort of patients with hepatitis C virus infection receiving treatment with Olysio and Sovaldi with or without ribavirin, was approximately $171,000, according to data presented at CROI 2015.

“The aim of this study was to estimate the cost per [sustained virologic response] of [simeprevir and sofosbuvir with or without ribavirin] in patients chronically infected with genotype 1 hepatitis C in a real-world setting,” Kian Bichoupan, PhD, of Icahn School of Medicine at Mount Sinai, said during his presentation at CROI.

Meeting News Coverage

Delayed HCV therapy may increase liver-related deaths

February 27, 2015
SEATTLE — Deferring treatment for hepatitis C virus infection 1 year or more after diagnosis or until evidence of advanced liver disease may increase liver-related…
Severe fibrosis, cirrhosis prevalent in birth cohort of HCV patients Meeting News Coverage

Severe fibrosis, cirrhosis prevalent in birth cohort of HCV patients

February 27, 2015
SEATTLE — Many adults with hepatitis C virus born between 1945 and 1965 had severe fibrosis or cirrhosis, according to data presented at CROI 2015.“Our…
ALLY-2: Daclatasvir/Sovaldi render high SVR rates in HIV/HCV patients Meeting News Coverage

ALLY-2: Daclatasvir/Sovaldi render high SVR rates in HIV/HCV patients

February 26, 2015
SEATTLE — A treatment regimen of daclatasvir and Sovaldi for 12 weeks produced high rates of sustained virologic response among patients with HIV and hepatitis C…
CME
HCV Consults: Volume 1, Number 2

HCV Consults: Volume 1, Number 2

This activity is supported by educational grants from AbbVie and Genentech.

Approved interferon-free therapy has already become entrenched among clinicians for patients with HCV genotypes 2 and…
More »
Meeting News Coverage Video
thumbnail for video 3895262652001

Early liver transplantation could improve survival rates for patients with alcoholic hepatitis

November 17, 2014
BOSTON — Ibrahim A. Hanouneh, MD, hepatologist at Cleveland Clinic, discussed results of a study that compared…
More »
CME
j64a_activity

CRITICAL ISSUES IN HBV: Considerations in Optimizing HBV Treatment

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

Hepatitis B virus (HBV) infection is a global epidemic with a worldwide burden. Physicians must address the importance…
More »
Meeting News Coverage

Average cost per SVR12 was $171,000 for Olysio, Sovaldi regimens

March 2, 2015
SEATTLE — The mean cost per sustained virologic response at 12 weeks among a cohort of patients with hepatitis C virus infection receiving…
Meeting News Coverage

Delayed HCV therapy may increase liver-related deaths

February 27, 2015
SEATTLE — Deferring treatment for hepatitis C virus infection 1 year or more after diagnosis or until evidence of advanced liver disease may…
Severe fibrosis, cirrhosis prevalent in birth cohort of HCV patients Meeting News Coverage

Severe fibrosis, cirrhosis prevalent in birth cohort of HCV patients

February 27, 2015
SEATTLE — Many adults with hepatitis C virus born between 1945 and 1965 had severe fibrosis or cirrhosis, according to data presented at CROI…
ALLY-2: Daclatasvir/Sovaldi render high SVR rates in HIV/HCV patients Meeting News Coverage

ALLY-2: Daclatasvir/Sovaldi render high SVR rates in HIV/HCV patients

February 26, 2015
SEATTLE — A treatment regimen of daclatasvir and Sovaldi for 12 weeks produced high rates of sustained virologic response among patients with…
Mark Sulkowski In the Journals

3D regimen plus ribavirin yields high SVR in patients with HIV/HCV

February 26, 2015
In the TURQUOISE-1 pilot study, a majority of patients coinfected with hepatitis C virus infection genotype 1 and HIV-1 achieved sustained virologic…
Meeting News Coverage

Patients with HIV/HCV may require ART switch to receive Olysio

February 24, 2015
In a cohort of patients coinfected with HIV and hepatitis C virus, a majority were required to undergo an antiretroviral therapy switch before…
In the Journals

Harvoni yields high SVR rates in patients coinfected with HCV/HIV

February 24, 2015
After treatment with Harvoni for hepatitis C virus infection, high rates of sustained virologic response were observed in treatment-naive patients…

Mylan to distribute both Sovaldi and Harvoni for HCV in India

February 23, 2015
Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan Inc., has entered into an agreement with Gilead Sciences to be an exclusive distributor…
Ethnicity increases risk for alcoholic liver disease In the Journals

Ethnicity increases risk for alcoholic liver disease

February 20, 2015
People of ethnic origin, mainly Hispanics, had an increased risk for alcoholic liver disease compared with Caucasians, according to new study…
In the Journals

Reaching SVR after antiviral therapy improves advanced fibrosis survival

February 19, 2015
Patients with advanced liver disease due to chronic hepatitis C virus had improved survival when achieving a sustained virologic response after…
More Headlines »
morganatic-roan
morganatic-roan